Producer in China; Tacrolimus; CAS: 104987-11-3

Model NO.: 104987-11-3
CAS: 104987-11-3
Mf: C44h69no12
MW: 804.02
Trademark: DKY
Transport Package: 25kg/Drums; 1kg/Bag
Specification: USP/BP/EP/CP
Origin: Made in China
HS Code: 1534706968
Model NO.: 104987-11-3
CAS: 104987-11-3
Mf: C44h69no12
MW: 804.02
Trademark: DKY
Transport Package: 25kg/Drums; 1kg/Bag
Specification: USP/BP/EP/CP
Origin: Made in China
HS Code: 1534706968
DKY hundred years specializing in the production of bulk drug manufacturers, the company is committed to chemical raw materials intermediates, biomedical technology as the core of the production, research and development.
Has hundreds of domestic and foreign major pharmaceutical manufacturers and research institutes to establish a stable and good relations of cooperation.
Welcome to business enterprises to negotiate business, hand in hand a total of raw materials industry peak.


Product Name:    Tacrolimus

CAS:    104987-11-3
MF:    C44H69NO12
MW:    804.02

Melting point     113-115°C
storage temp.     −20°C
solubility     DMSO: >3 mg/mL
form     solid
color     white
Purity: 99%
Storage: Shading, Confined Preservation
Delivery: by DHL, TNT, FedEx, Hkems, UPS, etc.
Specification: USP
HS Code: 15347069687
 


Chemical Properties    White Crystalline Solid
Usage    An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release.
Usage    FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
Usage    Tacrolimus (fujimycin) was discovered as a potent inhibitor of IL2 production in a targeted search for novel immunosuppressants. Tacrolimus acts by blocking T cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target IL-2. Tacrolimus inhibits the activity of FK-506 binding protein, Ca2+-dependent phosphatase and calcineurin, and activates NF-κB through phosphorylation and degradation of IκBα.
Usage    treatment of Cushing's syndrome
Usage    For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart,
.
 
Progesterone 57-83-0 USP EP BP
Medroxyprogesterone Acetate
 
71-58-9
 
USP
 
Megestrol Acetate
 
595-33-5
 
USP EP
 
Altrenogest
 
850-52-2
 
USP EP BP
17α-hydroxyprogesterone caproate 
 
630-56-8
 
USP
 
Norgesterone
 
13563-60-5
 
USP EP BP
Estriol
 
50-27-1
 
USP EP BP
 
 
107868-30-4
 
USP EP BP
DKY hundred years specializing in the production of bulk drug manufacturers, the company is committed to chemical raw materials intermediates, biomedical technology as the core of the production, research and development.
Has hundreds of domestic and foreign major pharmaceutical manufacturers and research institutes to establish a stable and good relations of cooperation.
Welcome to business enterprises to negotiate business, hand in hand a total of raw materials industry peak.


Product Name:    Tacrolimus

CAS:    104987-11-3
MF:    C44H69NO12
MW:    804.02

Melting point     113-115°C
storage temp.     −20°C
solubility     DMSO: >3 mg/mL
form     solid
color     white
Purity: 99%
Storage: Shading, Confined Preservation
Delivery: by DHL, TNT, FedEx, Hkems, UPS, etc.
Specification: USP
HS Code: 15347069687
 


Chemical Properties    White Crystalline Solid
Usage    An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release.
Usage    FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
Usage    Tacrolimus (fujimycin) was discovered as a potent inhibitor of IL2 production in a targeted search for novel immunosuppressants. Tacrolimus acts by blocking T cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target IL-2. Tacrolimus inhibits the activity of FK-506 binding protein, Ca2+-dependent phosphatase and calcineurin, and activates NF-κB through phosphorylation and degradation of IκBα.
Usage    treatment of Cushing's syndrome
Usage    For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart,
.
 
Progesterone 57-83-0 USP EP BP
Medroxyprogesterone Acetate
 
71-58-9
 
USP
 
Megestrol Acetate
 
595-33-5
 
USP EP
 
Altrenogest
 
850-52-2
 
USP EP BP
17α-hydroxyprogesterone caproate 
 
630-56-8
 
USP
 
Norgesterone
 
13563-60-5
 
USP EP BP
Estriol
 
50-27-1
 
USP EP BP
 
 
107868-30-4
 
USP EP BP